Experts discuss how the availability of bispecific therapies has influenced treatment paradigms in oncology and how bispecifics fit into current treatment algorithms for hematologic malignancies and solid tumors.
Video content above is prompted by the following:
Corticosteroid Premedication for Infliximab Remains Unnecessarily Common
July 8th 2025Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.
Read More